Australia markets closed

Xenon Pharmaceuticals Inc. (XENE)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
40.34+0.04 (+0.10%)
At close: 04:00PM EDT
40.34 0.00 (0.00%)
After hours: 04:02PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 3.05B
Enterprise value 2.34B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)3.61
Enterprise value/revenue 10.87k
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.26
52-week change 32.62%
S&P500 52-week change 325.61%
52-week high 350.99
52-week low 327.99
50-day moving average 340.31
200-day moving average 341.57

Share statistics

Avg vol (3-month) 3409.62k
Avg vol (10-day) 3280.41k
Shares outstanding 575.76M
Implied shares outstanding 675.88M
Float 869.99M
% held by insiders 10.38%
% held by institutions 1100.96%
Shares short (15 Aug 2024) 43.34M
Short ratio (15 Aug 2024) 47.97
Short % of float (15 Aug 2024) 44.44%
Short % of shares outstanding (15 Aug 2024) 44.41%
Shares short (prior month 15 July 2024) 43.27M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)30 June 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-18.92%
Return on equity (ttm)-26.71%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -233.68M
Net income avi to common (ttm)-199.06M
Diluted EPS (ttm)-2.73
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)721.53M
Total cash per share (mrq)9.52
Total debt (mrq)10.03M
Total debt/equity (mrq)1.19%
Current ratio (mrq)23.27
Book value per share (mrq)11.15

Cash flow statement

Operating cash flow (ttm)-153.55M
Levered free cash flow (ttm)-104.09M